Article Finder
Browse our vast collection of articles. Simply select a category on the left and find a list of related articles on the right.
Article Category
Article Title
- High or Low Blood Pressure May Raise the Risk of Dementia
- How Alcohol Might Affect Your Dementia Risk
- The Hidden Costs of Alzheimer’s Disease
- Susceptible to Scams? It May Be an Early Sign of Alzheimer’s Disease
- Alzheimer’s Caregivers May Benefit from Happiness Training
- Giving Up the Guns When a Family Member Has Alzheimer’s
- Care Management Program Is Reducing Need for Anti-anxiety Medication and Visits to the Hospital/Emergency Room
- Talking to a Loved One With Alzheimer’s
- 10 Powerful Ways to Commemorate Alzheimer’s Awareness Month
- Making the Most of Mealtimes for People With Alzheimer’s
- FOR MORE ARTICLES CLICK HERE
- Depression Increases the Risk of Alzheimer’s Disease
- Poor Sleep Tied to Rise in Alzheimer’s Protein in Blood
- Air Pollution Tied to Alzheimer’s Brain Changes
- The Tau of Alzheimer’s
- Anemia Tied to Alzheimer’s Risk
- ‘Squeezed’ Blood Vessels in the Brain May Contribute to Alzheimer’s Onset
- Hormone Therapy for Prostate Cancer Tied to Alzheimer’s Disease Risk
- Lack of Deep Sleep Tied to Alzheimer’s Brain Changes
- Inflammation in Middle Age Tied to Thinking and Memory Problems Later
- Frailty May Increase Susceptibility to Alzheimer’s Disease
- FOR MORE ARTICLES CLICK HERE
- Take Your Blood Pressure Meds. It May Reduce Your Alzheimer’s Risk.
- Drug Company to Pursue Approval of Aducanumab, New Drug for Alzheimer’s
- Drugs May Not Be the Best Choice for Easing the Agitation of Alzheimer’s
- Alzheimer’s Drug May Lead to Life-Threatening Muscle Disease
- Opioid Painkillers Increase Pneumonia Risk in People With Alzheimer’s Disease
- Drug Companies Halt Trials of Aducanumab for Alzheimer’s Disease
- Diabetes Treatments May Help Ward Off Alzheimer’s Disease
- Can Mushrooms Help Your Memory?
- Buyer Beware: Dietary Supplement’s Won’t Cure Alzheimer’s Disease
- Experimental Drug, Fails to Benefit Alzheimer’s Patients
- FOR MORE ARTICLES CLICK HERE
- A Daily Aspirin May Have Limited Brain Benefits
- For a Younger Brain, Try Walking, Gardening, Swimming or Dancing
- Moderate Drinking May Be Good for Your Brain
- Aerobic Exercise Shows Brain Benefits for Those at Risk of Alzheimer’s Disease
- Eating Flavonols, Found in Fruits, Vegetables and Tea, May Lower Alzheimer’s Risk
- Obesity at Midlife Tied to Increased Dementia Risk
- Reading and Writing May Be Good for the Brain
- Ski Study Shows How Exercise May Aid the Brain
- How Light May Help People with Alzheimer’s Disease
- Trans Fats Tied to Increased Alzheimer’s Risk
- FOR MORE ARTICLES CLICK HERE
- A Rare Genetic Mutation May Protect Against Alzheimer’s
- Income Drops in Young Adulthood May Impair Brain Health
- Blood Test for Alzheimer’s Grows Closer
- Are We Getting Closer to an Alzheimer’s Vaccine?
- Why More Women Than Men Have Alzheimer’s Disease
- Scientists get a ‘total surprise’ and a promising new clue for how to cure Alzheimer’s
- Some 44 Million People Have Alzheimer’s Worldwide
- Nearly 14 Million Americans Will Have Alzheimer’s Disease by 2060
- Alzheimer’s Rates Could Double in Coming Decades
- Combining Care Program With Medication Reduces Alzheimer’s Symptoms By 750%
- FOR MORE ARTICLES CLICK HERE
- Important Message from Us to You during COVID-19
- Lucretia V. Holden promoted to Executive Director at the Fisher Center
- The Fisher Center for Alzheimer’s Research Foundation Earns Coveted 4-Star Rating from Charity Navigator for the 8th Consecutive Year
- Fisher Center For Alzheimer’s Research Foundation Wins Fall 2018 Digital Health Awards®
- Fisher Center for Alzheimer’s Research Foundation Earns Gold Seal of Transparency from GuideStar
- The Fisher Center for Alzheimer’s Research Foundation Earns Coveted 4-Star Rating from Charity Navigator for the 7th Consecutive Year
- Hear Kent Karosen, President and CEO of the Fisher Center for Alzheimer’s Research Foundation, describe his new book and the power of art therapy
- Fisher Center Scientists link a Mutation That Protects Against the Development of Alzheimer’s Disease
- Newly Inducted Into the Basketball Hall of Fame, Shaquille O’Neal, Joins the Fisher Center for Alzheimer’s Research Foundation to Raise Funds for Groundbreaking Research in the Quest for a Cure
- Pat Summitt, legendary women’s basketball coach, dies at 64
- FOR MORE ARTICLES CLICK HERE
Drug for Agitation Could Actually Worsen Alzheimer’s Symptoms
February 21, 2005
February 21, 2005
A medication commonly prescribed for agitation and other behavioral problems in people with Alzheimer’s disease could actually make their condition worse, a new study reports. The study, however, was small, and much more needs to be learned about treating agitation and other “problem” behaviors in the millions of people afflicted with Alzheimer’s disease.
The drug, sold under the brand name Seroquel and known by doctors as quetiapine, has been approved to treat people with the psychiatric conditions schizophrenia and manic-depression (bipolar disorder). Doctors commonly also prescribe the drug to people with Alzheimer’s disease who are agitated and disruptive.
Problem behaviors occur in well over half of people with Alzheimer’s and become more common as the disease progresses. They are a major source of stress for people with Alzheimer’s as well as caregivers and nursing home staff who care for those with the memory-robbing illness.
A Small Study
Reporting in the British Medical Journal, researchers at the Institute of Psychiatry in London found that Seroquel could actually accelerate the rate of cognitive decline in those with Alzheimer’s. The scientists looked at 93 men and women who had Alzheimer’s and high levels of agitation and distress who were being cared for in nursing homes in England. They were divided into three groups. One group received a daily dose of Seroquel to combat behavioral complaints. Another group received rivastigmine, or Exelon, a drug used to treat the cognitive decline of Alzheimer’s, while the third group got a dummy pill (placebo).
The patients were tested for memory and cognitive skills as well as agitation levels to assess whether their disease had grown worse. After six months, the group receiving Seroquel did not show significant improvements in agitation scores compared to the other groups. As a group, they also had lower scores on memory and cognition compared to the group taking a placebo.
Spokespeople for AstraZeneca, the company that makes the drug, counter that Seroquel has been used safely and effectively to treat psychiatric conditions for years. They also point out that the current study was very small: More than half the patients actually dropped out of the study by the time it was completed. Problem behaviors in just a few patients, they say, skewed the final results, so that valid conclusions could not be drawn.
Experts agree that more research is needed into safe and effective treatments for common behavioral problems related to Alzheimer’s. Dr. Barry Reisberg, Director of the Fisher Alzheimer’s Disease Program at New York University School of Medicine and Professor in the Department of Psychiatry, says that like many of the drugs used to treat behavioral problems, Seroquel has not been tested extensively specifically in those with Alzheimer’s disease. He also notes that the drug has a sedative effect, which can interfere with cognition and mental functions, including memory, as long as the person is feeling its sedating effects.
Doctors commonly prescribe a wide variety of psychiatric drugs, including sedatives and psychosis-fighting medications, to help manage difficult behaviors in those with Alzheimer’s. Unfortunately, many of these medications have serious side effects and only limited effectiveness. More systematic research is needed into studying such drugs and finding ones that offer clear benefit. The Fisher Center for Alzheimer’s Research Foundation continues to be a leader in the search for a cure. Keep up with the latest research findings and learn more about the disease at their Web site, www.ALZinfo.org.
By www.ALZinfo.org, The Alzheimer’s Information Site. Reviewed by William J. Netzer, Ph.D., Fisher Center for Alzheimer’s Research Foundation at The Rockefeller University.
Source:
Clive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al: “Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial.” BMJ Online, Feb 2005; 10.1136/bmj.38369.459988.8F.
